<DOC>
	<DOCNO>NCT01556815</DOCNO>
	<brief_summary>Transarterial chemoembolization ( TACE ) widely use unresectable hepatocellular carcinoma ( HCC ) . However , hypoxia cause TACE survive tumor cell lead release angiogenic growth factor contribute poor outcome . Sorafenib block tumor cell proliferation angiogenesis . The hypothesis patient unresectable HCC may benefit sorafenib combination TACE .</brief_summary>
	<brief_title>Sorafenib Combined With Transarterial Chemoembolization Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Neoplasms Histologic Type</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients newly diagnose HCC accord European Association Study Liver criterion . BCLC stage B ChildPugh class A ECOG performance status 0 Etiology : Hepatitis B virus ( HBV ) infection Written inform consent ( approved Institutional Review Board [ IRB ] obtain prior study specific screen procedure Patient must able comply protocol Age 1880 year Haematology : Absolute neutrophil count ( ANC ) &gt; 1 x 109/L , Platelet count &gt; 40 x 109/L , Haemoglobin &gt; 9 g/dL ( may transfuse maintain exceed level ) Prothrombin time international normalized ratio &lt; 1.5 Biochemistry : Total bilirubin &lt; 2 mg/dL Serum creatinine &lt; 1.5 x upper limit normal Life expectancy &gt; 3 month Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5 x upper limit normal Other severe concomitant disease may reduce life expectancy uncontrolled hypertension Pregnancy ( positive serum pregnancy test ) lactation Uncontrolled hypertension Serious , nonhealing wound , ulcer , bone fracture Currently recent ( within 30 day prior start study treatment ) treatment another investigational drug participation another investigational study Clinically significant ( i.e . active ) cardiovascular disease example cerebrovascular accident ( ≤ 6 month prior study entry ) , myocardial infarction ( ≤ 6 month prior study entry ) , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication Evidence disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use Sorafenib/TACE patient high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Transarterial Chemoembolization</keyword>
	<keyword>HBV</keyword>
</DOC>